BRPI0809326B8 - métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera - Google Patents
métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesferaInfo
- Publication number
- BRPI0809326B8 BRPI0809326B8 BRPI0809326A BRPI0809326A BRPI0809326B8 BR PI0809326 B8 BRPI0809326 B8 BR PI0809326B8 BR PI0809326 A BRPI0809326 A BR PI0809326A BR PI0809326 A BRPI0809326 A BR PI0809326A BR PI0809326 B8 BRPI0809326 B8 BR PI0809326B8
- Authority
- BR
- Brazil
- Prior art keywords
- controlled release
- microsphere
- active ingredient
- exendin
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Abstract
métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera. são proporcionadas uma composição de liberação controlada e microesferas de liberação controlada contendo exendina como ingrediente ativo e um método de preparação da mesma. mais especificamente, são proporcionados uma composição de liberação controlada contendo exendina como ingrediente ativo, um polímero biodegradável como uma viscosidade especifica e materiais de revestimento, tendo elevada biodisponibilidade e exibindo liberação sustentada do ingrediente ativo numa concentração efetiva para um certo período sem uma explosão inicial excessiva do ingrediente ativo: microesferas de liberação controlada contendo um núcleo incluindo exendina como ingrediente ativo e um polímero biodegradável e uma camada de revestimento que recobre o núcleo; e um método de preparação de microesferas de liberação controlada incluindo as etapas de misturar uma exendina, um polímero biodegradável e um solvente, remover o solvente a partir da mistura para preparar a microesferas endurecidas e revestimento sobre a superfície de cada microesfera.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070029586A KR100805208B1 (ko) | 2007-03-27 | 2007-03-27 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
PCT/KR2008/000397 WO2008117927A1 (en) | 2007-03-27 | 2008-01-22 | Composition and microsphere for controlled-release of exendin, and method of preparing the same |
KR10-2007-0029586 | 2008-03-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0809326A2 BRPI0809326A2 (pt) | 2014-09-23 |
BRPI0809326B1 BRPI0809326B1 (pt) | 2020-10-13 |
BRPI0809326B8 true BRPI0809326B8 (pt) | 2021-05-25 |
Family
ID=39382592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0809326A BRPI0809326B8 (pt) | 2007-03-27 | 2008-01-22 | métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera |
Country Status (16)
Country | Link |
---|---|
US (1) | US9155702B2 (pt) |
EP (1) | EP2134329B1 (pt) |
JP (1) | JP5135428B2 (pt) |
KR (1) | KR100805208B1 (pt) |
CN (1) | CN101646424B (pt) |
AU (1) | AU2008230297B2 (pt) |
BR (1) | BRPI0809326B8 (pt) |
CA (1) | CA2682499C (pt) |
ES (1) | ES2528282T3 (pt) |
IL (1) | IL201024A (pt) |
MX (1) | MX2009010280A (pt) |
MY (1) | MY150087A (pt) |
PL (1) | PL2134329T3 (pt) |
RU (1) | RU2463040C2 (pt) |
WO (1) | WO2008117927A1 (pt) |
ZA (1) | ZA200906381B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0810140A2 (pt) | 2007-04-19 | 2014-10-29 | Dong A Pharm Co Ltd | Composição de microempresa biodegradável adequada para a liberação controlada de um peptídeo de controle de glicose e formulação da mesma |
US9292307B2 (en) | 2008-07-30 | 2016-03-22 | Kyocera Corporation | User interface generation apparatus |
US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
CN102370611B (zh) * | 2010-08-17 | 2013-09-18 | 东莞太力生物工程有限公司 | 一种包含exendin-4的温度敏感型水凝胶及其注射剂 |
WO2012098188A1 (en) * | 2011-01-19 | 2012-07-26 | Novo Nordisk A/S | Glp-1 particles and compositions |
WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
CN105688188A (zh) * | 2011-11-18 | 2016-06-22 | 瑞泽恩制药公司 | 聚合物蛋白微粒 |
CN102688198B (zh) * | 2012-06-19 | 2015-04-15 | 广州帝奇医药技术有限公司 | 多肽药物缓释微球制剂及其制备方法 |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
CN104107165B (zh) * | 2013-04-17 | 2018-11-30 | 长春百益制药有限责任公司 | 一种艾塞那肽微球制剂、其制备方法及其应用 |
CN104840415B (zh) | 2014-02-19 | 2019-03-15 | 香港浸会大学 | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 |
JP2017511371A (ja) * | 2014-04-16 | 2017-04-20 | シャンドン ルイ ファーマシューティカル カンパニー リミテッド | エクセナチド含有組成物及びその製造方法 |
WO2015175545A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
US9480640B2 (en) * | 2014-09-24 | 2016-11-01 | Hongkai Zhang | Nano freeze dry process of preparation of highly bioactive agent and its method of use |
AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
NZ740665A (en) | 2015-09-21 | 2023-04-28 | Teva Pharmaceuticals Int Gmbh | Sustained release olanzapine formulations |
AU2016338410B2 (en) | 2015-10-14 | 2021-07-15 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
CN107405307B (zh) * | 2015-12-22 | 2020-11-10 | 四川科伦药物研究院有限公司 | 一种艾塞那肽微球制剂及其制备方法 |
EP3528836A1 (en) | 2016-10-20 | 2019-08-28 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
US20200353127A1 (en) * | 2018-01-10 | 2020-11-12 | G2Gbio, Inc. | Collagen peptide-containing polycaprolactone microsphere filler and preparation method therefor |
AU2019401868B2 (en) * | 2018-12-17 | 2023-07-27 | G2Gbio, Inc. | Sustained-release injection comprising deslorelin, and preparation method therefor |
WO2021020885A1 (ko) | 2019-07-29 | 2021-02-04 | 주식회사 펩트론 | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 |
CN114206374A (zh) * | 2019-07-29 | 2022-03-18 | 佩特通公司 | 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物 |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US5271961A (en) * | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
GB9210574D0 (en) | 1992-05-18 | 1992-07-01 | Ca Nat Research Council | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
JPH09315975A (ja) | 1995-09-28 | 1997-12-09 | Takeda Chem Ind Ltd | 2−ピペラジノン−1−酢酸誘導体の徐放剤 |
JP4900984B2 (ja) | 1997-07-15 | 2012-03-21 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
AU770712B2 (en) | 1999-01-14 | 2004-02-26 | Amylin Pharmaceuticals, Inc. | Methods for glucagon suppression |
KR100675711B1 (ko) | 1999-01-14 | 2007-02-01 | 아밀린 파마슈티칼스, 인크. | 신규 엑센딘 아고니스트 제제 및 이의 투여 방법 |
PT1246638E (pt) | 2000-01-10 | 2004-12-31 | Amylin Pharmaceuticals Inc | Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia |
JP5160005B2 (ja) | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
KR100566573B1 (ko) | 2002-04-13 | 2006-03-31 | 주식회사 펩트론 | Lhrh 동족체를 함유하는 서방성 미립구의 제조방법 |
WO2004035762A2 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
EA200601904A1 (ru) * | 2004-04-15 | 2007-02-27 | Алкермес, Инк. | Система отсроченного высвобождения лекарственного средства на основе полимеров |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
PL1786400T3 (pl) * | 2004-08-12 | 2009-08-31 | Quest Pharmaceutical Services | Kompozycje farmaceutyczne do dostarczania biologicznie czynnych związków metodą kontrolowanego uwalniania |
EP1824460B1 (en) * | 2004-11-10 | 2014-12-24 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
-
2007
- 2007-03-27 KR KR1020070029586A patent/KR100805208B1/ko active IP Right Grant
-
2008
- 2008-01-22 MY MYPI20093763A patent/MY150087A/en unknown
- 2008-01-22 US US12/532,311 patent/US9155702B2/en active Active
- 2008-01-22 RU RU2009136655/15A patent/RU2463040C2/ru active
- 2008-01-22 ES ES08712168.7T patent/ES2528282T3/es active Active
- 2008-01-22 AU AU2008230297A patent/AU2008230297B2/en active Active
- 2008-01-22 PL PL08712168T patent/PL2134329T3/pl unknown
- 2008-01-22 MX MX2009010280A patent/MX2009010280A/es active IP Right Grant
- 2008-01-22 EP EP08712168.7A patent/EP2134329B1/en active Active
- 2008-01-22 BR BRPI0809326A patent/BRPI0809326B8/pt active IP Right Grant
- 2008-01-22 CA CA2682499A patent/CA2682499C/en active Active
- 2008-01-22 CN CN200880009933XA patent/CN101646424B/zh active Active
- 2008-01-22 WO PCT/KR2008/000397 patent/WO2008117927A1/en active Application Filing
- 2008-01-22 JP JP2010500816A patent/JP5135428B2/ja active Active
-
2009
- 2009-09-14 ZA ZA2009/06381A patent/ZA200906381B/en unknown
- 2009-09-17 IL IL201024A patent/IL201024A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL201024A (en) | 2014-01-30 |
EP2134329A4 (en) | 2013-07-10 |
AU2008230297A1 (en) | 2008-10-02 |
CA2682499C (en) | 2013-01-08 |
JP5135428B2 (ja) | 2013-02-06 |
IL201024A0 (en) | 2010-05-17 |
MX2009010280A (es) | 2009-10-12 |
RU2463040C2 (ru) | 2012-10-10 |
RU2009136655A (ru) | 2011-05-10 |
US9155702B2 (en) | 2015-10-13 |
ES2528282T3 (es) | 2015-02-06 |
CN101646424A (zh) | 2010-02-10 |
CA2682499A1 (en) | 2008-10-02 |
PL2134329T3 (pl) | 2015-07-31 |
WO2008117927A1 (en) | 2008-10-02 |
AU2008230297B2 (en) | 2010-07-29 |
BRPI0809326B1 (pt) | 2020-10-13 |
EP2134329B1 (en) | 2015-01-07 |
JP2010522743A (ja) | 2010-07-08 |
CN101646424B (zh) | 2013-03-20 |
BRPI0809326A2 (pt) | 2014-09-23 |
EP2134329A1 (en) | 2009-12-23 |
ZA200906381B (en) | 2010-11-24 |
MY150087A (en) | 2013-11-29 |
US20100136126A1 (en) | 2010-06-03 |
KR100805208B1 (ko) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0809326B8 (pt) | métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera | |
BR112013029422A2 (pt) | cápsulas núcleo-revestimento | |
BR112012026953A8 (pt) | Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica | |
BRPI0921687A8 (pt) | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. | |
CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
WO2008118133A3 (en) | Silk microspheres for encapsulation and controlled release | |
WO2010056065A3 (en) | Method for preparing microspheres and microspheres produced thereby | |
WO2012011740A3 (en) | Method for preparing microspheres and microspheres produced thereby | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
UY31406A1 (es) | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". | |
BRPI0721369A2 (pt) | Péletes que compreendem uma matriz de substância ativa e um revestimento polimérico, e um método para produzir os referidos péletes | |
BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
CR11740A (es) | Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada | |
CL2014001172A1 (es) | Un portador para la liberacion controlada de agentes activos que comprende un nucleo de cabonato de calcio y un agente activo, y un recubrimiento que encapsula al nucleo; metodo para preparar el portador, y su uso en controlar la liberacion de un agente activo | |
BRPI0810552A2 (pt) | Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa. | |
BR112012033073A2 (pt) | micropartículas de liberação prolongada, preparação contendo micropartículas de liberação prolongada, grânulo, e, método para preparar as micropartículas de liberação prolongada | |
BRPI0821616B8 (pt) | composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma | |
CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
CL2007002970A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
CR11864A (es) | Preparación de formas farmacéuticas relajantes de músculos esqueléticos de liberación controlada | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
BRPI0901301A2 (pt) | composição para modelar cabelos, e, métodos para modelar cabelo e para fabricar um polìmero | |
BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
AR061165A1 (es) | Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas | |
WO2010014176A3 (en) | Preparation method of biodegradable micro-particles containing drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |